SAN FRANCISCO--(BUSINESS WIRE)--Noetik, an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer. Dr. Virani brings a rich background in both business development and clinical development, with experience building therapeutics portfolios at large global organizations, and securing transformational partnerships at innovative biotech organizations.

旧金山--（商业新闻短讯）--Noetik是一家人工智能本土生物技术公司，利用先进的机器学习和专有数据来发现和开发精确的癌症免疫疗法，宣布任命Shafique Virani博士为首席商务官。Virani博士在业务开发和临床开发方面都有丰富的背景，在大型全球组织中建立治疗组合的经验，以及在创新生物技术组织中建立转型伙伴关系的经验。

His deep strategic expertise will be critical in driving multiple unique and diverse paths of value generation from Noetik’s innovative platform..

他深厚的战略专业知识对于推动Noetik创新平台的多种独特多样的价值创造途径至关重要。。

'We are thrilled to welcome Shaf to our team as Chief Business Officer. His unique expertise spanning business development, clinical development, and life science company formation, will be massively impactful in turning innovative scientific insights from our AI-enabled platform into partnerships and programs with the potential to produce differentiated therapeutics.

“我们非常高兴地欢迎Shaf作为首席商务官加入我们的团队。他在业务开发、临床开发和生命科学公司组建方面的独特专业知识，将对将我们人工智能平台的创新科学见解转化为具有产生差异化治疗潜力的伙伴关系和计划产生巨大影响。

His proven track record in establishing transformative collaborations will significantly accelerate our mission to make groundbreaking advances for cancer patients,' said Ron Alfa, M.D., Ph.D., CEO & Co-Founder, Noetik..

诺提克首席执行官兼联合创始人、医学博士罗恩·阿尔法（RonAlfa）说，他在建立变革性合作方面的良好记录将大大加速我们为癌症患者取得突破性进展的使命。。

Prior to joining Noetik, Dr. Virani served as Recursion’s Chief Corporate Development Officer, as well as the interim Chief Medical Officer as part of his tenure. At Recursion, he was instrumental in forging partnerships with Bayer and Roche/Genentech, the latter being one of the largest drug discovery partnerships ever consummated in industry.

在加入Noetik之前，Virani博士曾担任Recursion的首席企业发展官，并在任期内担任临时首席医疗官。在Recursion，他与拜耳和罗氏/基因泰克建立了合作伙伴关系，后者是业界有史以来最大的药物发现合作伙伴之一。

Prior to joining Recursion, Dr. Virani was Chief Executive Officer of Navire Pharma and CoA Therapeutics (each a subsidiary of BridgeBio Pharma)..

在加入Recursion之前，Virani博士曾担任Navire Pharma和CoA Therapeutics（均为BridgeBio Pharma的子公司）的首席执行官。。

During his 13-year long tenure at Roche/Genentech as Vice President and Global Head of Neuroscience, Ophthalmology and Rare disease partnering, Dr. Virani built a portfolio of medicines including Risdiplam for spinal muscular atrophy, Enspryng for neuromyelitis optica spectrum disorder and several therapeutics in the mid-late stage clinical pipeline through business development, licensing and acquisitions.

在罗氏/基因泰克（Roche/Genentech）担任副总裁兼神经科学、眼科和罕见病合作全球负责人的13年任期内，Virani博士通过业务开发、许可和收购，建立了一系列药物，包括用于治疗脊髓性肌萎缩症的利培林、用于治疗视神经脊髓炎谱系障碍的Enspring以及中晚期临床管道中的几种治疗药物。

Dr. Virani trained as a neurosurgeon in Cambridge, UK and Boston and received his M.D. from the University of Nottingham..

维拉尼博士曾在英国剑桥和波士顿接受过神经外科医生的培训，并获得了诺丁汉大学的医学博士学位。。

“Noetik was founded to not only conduct impactful science, but to bring together some of the most talented people in the industry to build a transformative ML-enabled therapeutics company. Shaf brings a unique combination of skills, bridging pharmaceutical business acumen with clinical development insight,” said Jacob Rinaldi, Ph.D., CSO & Co-Founder, Noetik..

Noetik博士、CSO和联合创始人Jacob Rinaldi说：“Noetik的成立不仅是为了进行有影响力的科学研究，而且是为了汇集业内一些最有天赋的人才，建立一家变革性的ML治疗公司。Shaf带来了独特的技能组合，将制药商业敏锐度与临床开发洞察力联系起来。”。。

As Chief Business Officer, Dr. Virani will accelerate Noetik’s mission through both business development and portfolio strategy by identifying and facilitating strategically impactful transactions. His leadership will be crucial in transitioning the initial therapeutic pipeline from the research phase to clinical trials, underscoring Noetik’s commitment to developing impactful precision cancer immunotherapies..

作为首席商务官，Virani博士将通过识别和促进具有战略影响力的交易，通过业务发展和投资组合战略加速Noetik的使命。他的领导对于将最初的治疗流程从研究阶段过渡到临床试验至关重要，这突显了Noetik致力于开发有影响力的精确癌症免疫疗法。。

'Joining Noetik as Chief Business Officer was an obvious decision. The team are some of the most passionate people I have worked with before and I am certain will move the needle in cancer therapeutics. The platform capabilities they have built in such a short amount of time are truly impressive in terms of furthering precision medicine in oncology using modern tools and technologies - I’m excited for the opportunity to blend my background in business development, strategic partnerships, and clinical insight with the innovative spirit of this team,” said Dr.

加入诺提克担任首席商务官是一个显而易见的决定。这个团队是我之前共事过的最有激情的人之一，我相信他们会在癌症治疗领域有所作为。他们在如此短的时间内建立的平台能力在使用现代工具和技术进一步推进肿瘤学中的精准医学方面确实令人印象深刻-我很高兴有机会将我在业务开发，战略合作伙伴关系和临床见识方面的背景与该团队的创新精神相结合，”Dr。

Virani. “Together, we're set to redefine what's possible in our industry, driven by a shared vision for transformative impact on patients.'.

维拉尼。“在对患者产生变革性影响的共同愿景的推动下，我们将共同重新定义我们行业的可能性。”。

About Noetik

Noetik

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies. The company is based in San Francisco, CA. For more information, visit https://www.noetik.ai/.

Noetik是一家人工智能本土生物技术公司。通过利用自我监督学习和人类多模式数据的潜力，Noetik旨在发现更精确的免疫疗法。该公司总部位于加利福尼亚州旧金山。有关更多信息，请访问https://www.noetik.ai/.